Pharmaka mit Wirkung auf den Respirationstrakt

  • Eberhard Hackenthal
Part of the Springer-Lehrbuch book series (SLB)


Die häufigsten obstruktiven Atemwegserkrankungen sind das Asthma bronchiale und die chronische obstrukte Bronchitis, die sowohl in der Pathogenese als auch der Symptomatologie Gemeinsamkeiten haben (Abb.32.1).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adam D, Ferlinz R, Frei R, Geisler L, Knothe H, Lode H, Shah P (1992) Antibakterielle Therapie bei infektiösen Bronchialerkrankungen. Med Monatsschr Pharm 15:100–105PubMedGoogle Scholar
  2. Anderson GP, Coyle AJ (1994) TH2 and „TH2-like“ cells in allergy and asthma pharmacological perspectives. Trends Pharmacol Sci 15:324–332PubMedCrossRefGoogle Scholar
  3. Asthma im Kindesalter (1992) Arzneimittelbrief 28:97–99Google Scholar
  4. Barnes PJ (1989) A new approach to the treatment of asthma. N Engl J Med 321:1517–1527PubMedCrossRefGoogle Scholar
  5. Barnes PJ (1991) Biochemistry of asthma. Trends Biochem Sci 16:365–369PubMedCrossRefGoogle Scholar
  6. Barnes PJ (1994) Cytokines as mediators of chronic asthma. Am J Respir Crit Care Med 150:542–549Google Scholar
  7. Barnes PJ, Adcock I (1992) Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol Sci 14:436–441CrossRefGoogle Scholar
  8. Barnes PJ, Chung KF (1992) Questions about inhaled β2-adrenoceptor agonists in asthma. Trends Pharmacol Sci 13:20–23PubMedCrossRefGoogle Scholar
  9. Barnes PJ, Pauwels R (1994) Theophylline in the management of asthma: time for reappraisal. Eur Respir J 7:579–591PubMedCrossRefGoogle Scholar
  10. Boulet LP (1994) Long- versus short-acting β2-agonists. Implications for drug therapy. Drugs 47:207–222PubMedCrossRefGoogle Scholar
  11. Brogden RN, Faulds D (1991) Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airway disease. Drugs 42:895–912PubMedCrossRefGoogle Scholar
  12. Chung KF, Barnes PJ (1988) PAF-antagonists. Their potential role in asthma. Drugs 35:93–103PubMedCrossRefGoogle Scholar
  13. Clissold SP, Heel RC (1984) Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 28:485–518PubMedCrossRefGoogle Scholar
  14. Coleman RA, Johnson M, Nials AT, Vardey CJ (1996) Exosites: their current status, and their relevance to the action of long-acting β2-adrenoceptor agonists. Trends in Pharmacol Sci 17:324–330CrossRefGoogle Scholar
  15. Collis MG, Hourani DMP (1993) Adenosine receptor subtypes. Trends Pharmacol Sci 14:360–366PubMedCrossRefGoogle Scholar
  16. Gianaris PG, Golish JA (1993) Treatment of bronchospastic disorders in the 1990s. Drugs 46:1–6PubMedCrossRefGoogle Scholar
  17. Giembycz MA (1996) Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists. Trends in Pharmacol Sci 17:331–336CrossRefGoogle Scholar
  18. Gonzalez JP, Brogden RN (1987) Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs. 34:560–577PubMedCrossRefGoogle Scholar
  19. Halliday HL (1996) Natural vs Synthetic surfactants in neonatal respiratory distress syndrome. Drugs 51:226–237PubMedCrossRefGoogle Scholar
  20. Hofmann F, Ludwig A, Pfeiffer A, Raeburn D, Giembycz MA (eds) (1994) Cyclic GMP and the control of airways smooth muscle tone. In: Airways smooth muscle biochemical control of contraction and relaxation. Birkhäuser, Basel, pp 253–269Google Scholar
  21. Howarth PH, Bradding P, Montefort S et al. (1994) Mucosal inflammation and asthma. Am J Respir Crit Care Med 150:518–522Google Scholar
  22. Internationaler Consensus-Bericht (1993) zur Diagnose und Behandlung des Asthma bronchiale. Pneumologie 47:245–288Google Scholar
  23. Irwin RS, Curley FJ, Bennett FM (1993) Appropriate use of antitussives and protussives. Drugs 46:80–91PubMedCrossRefGoogle Scholar
  24. Knight DA, Stewart GA, Thompson PJ (1994) The respiratory epithelium and airway smooth muscle homeostasis: its relevance to asthma. Clin Exp Allergy 24:698–706PubMedCrossRefGoogle Scholar
  25. Kroegel C, Herzog V, Knöchel B, et al (1996) 5-Lipoxigenase-Inhibitoren und Leukotrien-Rezeptorantagonisten. Arzneimittelther. 14:299–309Google Scholar
  26. Linden J (1994) Cloned adenosine A3-receptors. Pharmacological properties, species differences and receptor function. Trends Pharmacol Sci 15:298–306PubMedCrossRefGoogle Scholar
  27. Magnussen H (1993) Der schwere und lebensbedrohliche Asthmaanfall. Internist 36:779–784Google Scholar
  28. McFadden ER, Hejal R (1995) Asthma. Lancet 345:1215–1220PubMedCrossRefGoogle Scholar
  29. McGill KA, Busse WW (1996) Zileuton. Lancet 348:519–524PubMedCrossRefGoogle Scholar
  30. Morley J (1993) Immunopharmacology of asthma. Trends Pharmacol Sci 14:208–213PubMedCrossRefGoogle Scholar
  31. Morley J (1994) K+ channel openers and suppresion of airway hyperreactivity. Trends Pharmacol Sci 15:463–468PubMedCrossRefGoogle Scholar
  32. Pauwels RA (1989) New aspects of the therapeutic potential of theophyllin in asthma. J Allergy Clin Immunol 83:548–553PubMedCrossRefGoogle Scholar
  33. Persson CGA (1987) The pharmacology of antiasthmatic xanthines and the role of adenosine. Asthma Rev 1:61–93Google Scholar
  34. Reed CE (1986) New therapeutic approaches in asthma. J Allergy Clin Immunol 77:537–543PubMedCrossRefGoogle Scholar
  35. Rhoden KJ (1988) Inhibition of cholinergic neurotransmission in human airways by β-2-adrenoceptors. J Appl Physiol 65:700–705PubMedGoogle Scholar
  36. Richardson P (1987) Oral N-acetylcysteine: how does it act? Eur J Respir Dis 70:71–72PubMedGoogle Scholar
  37. Rossing TA (1989) Methylxanthines in 1989. Ann Intern Med 110:502–504PubMedGoogle Scholar
  38. Schmidt M, Martin E (1994) Asthma und Antiasthmatika. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  39. Siegers CP (1994) Adjuvante Atemwegstherapeutika. Med Monatsschr Pharm 17:302–305PubMedGoogle Scholar
  40. Spitzer WO, Suissa S, Ernst P et al. (1992) The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 326:501–506PubMedCrossRefGoogle Scholar
  41. Szczeklik A (1986) Analgesics, allergy and asthma. Drugs 32 [Suppl 4]:148–163PubMedCrossRefGoogle Scholar
  42. Thesen R (1993) Colfosceril zur Surfactantsubstitution. Pharmazeut Ztg 138:1793–1798Google Scholar
  43. Torphy TJ (1994) β-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol Sci 15:370–374PubMedCrossRefGoogle Scholar
  44. Ukena D, Keller A, Sybrecht GW (1994) Theophyllin. Neues zu einem bewährten Medikament. Med Klin 89:668–674Google Scholar
  45. Weinberger M, Hendeles L (1996) Theophylline in Asthma. NEJM 334:1380–1388PubMedCrossRefGoogle Scholar
  46. Wettengel R, Leupold W, Magnussen H, Nolte D, Schultze-Werninghaus G, Wörth H (1993) Management von Asthma bronchiale. Arzneimitteltherapie 11:129–133Google Scholar
  47. Woolcock AJ (1990) β-Agonists and asthma mortality. Drugs 40:653–656PubMedCrossRefGoogle Scholar
  48. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE (1990) Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 336:1396–1399PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Eberhard Hackenthal

There are no affiliations available

Personalised recommendations